Targeting of VISTA with Cyclic Peptide-Based PET Tracers for Immune Checkpoint Imaging
Molecular Pharmaceutics · 04.05.2026 · 23 (5) · 3218-3227
DOI: 10.1021/acs.molpharmaceut.6c00318 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 14.04.2026. Verfasst von Han Feng und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Henan Provincial People's Hospital and People's Hospital of Zhengzhou University, Zhengzhou 450003, China. Hauptthemen laut MEDLINE: Peptides, Cyclic, Positron-Emission Tomography, Radiopharmaceuticals, B7 Antigens. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Natural Science Foundation of Henan Province, National Natural Science Foundation of China, Henan Provincial Medical Science and Technology Project.
Abstract (Originalsprache)
Given the distinct roles of VISTA in immune regulation, a better visualization of VISTA expression could clarify the tumor immune status and predict the responses to immunotherapy. However, only a few targeted probes are in development and insufficient to fulfill clinical demands. In this study, based on cyclic peptide antagonist AP1049, three novel radiotracers, [68Ga]Ga-AP1049, [68Ga]Ga-AHX-AP1049, and [68Ga]Ga-Pip-AP1049, were designed and developed for targeting and imaging VISTA in cancers. Molecular dynamics simulation revealed the better binding of NOTA-Pip-AP1049 for VISTA protein than that of NOTA-AP1049 and NOTA-AHX-AP1049. Protein binding assays demonstrated their high specificity and affinity with IC50 values of 58.10, 23.34, and 17.56 nM, respectively. The B16-F10 tumor uptake of three tracers was significant and decreased over time within 120 min, with tumor uptake values of 1.02 ± 0.21, 1.56 ± 0.21, and 1.89 ± 0.29 %ID/cc and tumor/muscle ratios of 2.36 ± 0.36, 3.10 ± 0.51, and 4.06 ± 0.71 at 30 min post-injection, respectively. Their in vivo specificity were verified by blocking studies. Furthermore, [68Ga]Ga-Pip-AP1049 PET could detect varying VISTA expression in B16-F10, 4T1, MC38, and CT26 xenograft models with tumor uptake values of 2.71 ± 0.43, 2.32 ± 0.44, 1.17 ± 0.30, and 0.85 ± 0.17 %ID/cc, which were in consistent with percentages of VISTA+ cells (r = 0.8712, P < 0.0001). Biodistribution data suggested their renal excretion and favorable pharmacokinetics. In conclusion, [68Ga]Ga-Pip-AP1049 is a promising tracer for PET imaging of VISTA expression in tumor microenvironment, indicating its potential as a companion diagnostic of immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Henan Provincial People's Hospital and People's Hospital of Zhengzhou University, Zhengzhou 450003, China.
- Department of Nuclear Medicine, Henan Key Laboratory of Novel Molecular Probes and Clinical Translation in Nuclear Medicine, Henan Provincial People's Hospital and People's Hospital of Zhengzhou University, Zhengzhou 45…
ORCID-Profile: Xiaobo Wang
Förderung
- Natural Science Foundation of Henan Province
- National Natural Science Foundation of China
- Henan Provincial Medical Science and Technology Project
Zitieren
APA
Feng, H., Tian, X., Li, X., Duan, L., Li, B., Wu, X., Gao, Y., & Wang, X. (2026). Targeting of VISTA with Cyclic Peptide-Based PET Tracers for Immune Checkpoint Imaging. Molecular Pharmaceutics, 23(5), 3218-3227. https://doi.org/10.1021/acs.molpharmaceut.6c00318
Vancouver
Feng H, Tian X, Li X, Duan L, Li B, Wu X, et al. Targeting of VISTA with Cyclic Peptide-Based PET Tracers for Immune Checkpoint Imaging. Molecular Pharmaceutics. 2026;23(5):3218-3227. doi:10.1021/acs.molpharmaceut.6c00318
BibTeX
@article{Feng2026,
author = {Feng, Han and Tian, Xiaoting and Li, Xiaofei and Duan, Lili and Li, Bo and Wu, Xinyu and Gao, Yongju and Wang, Xiaobo},
title = {Targeting of VISTA with Cyclic Peptide-Based PET Tracers for Immune Checkpoint Imaging},
journal = {Molecular Pharmaceutics},
year = {2026},
volume = {23},
number = {5},
pages = {3218--3227},
doi = {10.1021/acs.molpharmaceut.6c00318}
}
EUVIMED